Tilray Brands (TLRY) Projected to Post Earnings on Thursday

Tilray Brands (NASDAQ:TLRY) is expected to be posting its Q1 2026 results before the market opens on Thursday, October 9th. Analysts expect Tilray Brands to post earnings of ($0.03) per share and revenue of $205.7510 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earningresults page for the latest details on the call scheduled for Thursday, October 9, 2025 at 8:30 AM ET.

Tilray Brands (NASDAQ:TLRY) last posted its earnings results on Monday, July 28th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. The business had revenue of $224.54 million for the quarter, compared to analyst estimates of $250.41 million. Tilray Brands had a negative net margin of 265.69% and a negative return on equity of 6.83%. On average, analysts expect Tilray Brands to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Tilray Brands Stock Down 4.3%

Tilray Brands stock opened at $1.66 on Thursday. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.46 and a quick ratio of 1.49. Tilray Brands has a fifty-two week low of $0.35 and a fifty-two week high of $1.86. The firm has a fifty day moving average price of $1.09 and a two-hundred day moving average price of $0.71. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -0.72 and a beta of 1.98.

Insider Buying and Selling at Tilray Brands

In other news, CEO Irwin D. Simon acquired 165,000 shares of the stock in a transaction dated Wednesday, July 30th. The shares were acquired at an average cost of $0.61 per share, for a total transaction of $100,650.00. Following the completion of the transaction, the chief executive officer owned 3,941,633 shares in the company, valued at approximately $2,404,396.13. This trade represents a 4.37% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Tilray Brands

Several institutional investors and hedge funds have recently bought and sold shares of TLRY. Marex Group plc bought a new position in shares of Tilray Brands during the 2nd quarter worth about $40,000. State of Wyoming raised its position in Tilray Brands by 38.7% in the second quarter. State of Wyoming now owns 334,576 shares of the company’s stock worth $139,000 after purchasing an additional 93,411 shares in the last quarter. Corient Private Wealth LLC raised its position in Tilray Brands by 100.2% in the second quarter. Corient Private Wealth LLC now owns 388,366 shares of the company’s stock worth $161,000 after purchasing an additional 194,369 shares in the last quarter. Tidal Investments LLC lifted its stake in Tilray Brands by 15.0% during the second quarter. Tidal Investments LLC now owns 28,971,835 shares of the company’s stock worth $12,006,000 after purchasing an additional 3,776,410 shares during the period. Finally, Hilton Capital Management LLC acquired a new stake in Tilray Brands during the second quarter valued at approximately $41,000. Institutional investors own 9.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on TLRY shares. Wall Street Zen lowered Tilray Brands to a “strong sell” rating in a research note on Saturday, July 5th. Jefferies Financial Group upped their price target on Tilray Brands from $1.50 to $2.00 and gave the stock a “buy” rating in a report on Monday, August 25th. Finally, Zelman & Associates restated a “neutral” rating on shares of Tilray Brands in a research note on Tuesday, July 29th. Two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $1.94.

Tilray Brands Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.